Viyash Life Sciences Private
Viyash Life Sciences Private, a prominent player in the pharmaceutical and biotechnology sectors, is headquartered in India. Established in 2010, the company has rapidly expanded its operations across key regions, focusing on innovative solutions in drug development and manufacturing. Viyash Life Sciences is renowned for its commitment to quality and excellence, offering a diverse range of products, including active pharmaceutical ingredients (APIs) and finished dosage forms. Their unique approach combines cutting-edge technology with rigorous quality control, ensuring that they meet the highest industry standards. With a strong market position, Viyash Life Sciences has achieved significant milestones, including partnerships with leading global firms and recognition for its contributions to healthcare. The company continues to drive advancements in life sciences, making a meaningful impact on patient care and treatment outcomes.
DitchCarbon Score
How does Viyash Life Sciences Private's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viyash Life Sciences Private's score of 17 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Viyash Life Sciences Private's reported carbon emissions
In 2023, Viyash Life Sciences Private reported significant carbon emissions, totalling approximately 53,362,700 kg CO2e for Scope 1 and about 32,333,760 kg CO2e for Scope 2. Notably, there were no reported emissions under Scope 3. This brings their total emissions to around 85,696,460 kg CO2e. Viyash Life Sciences has committed to achieving net-zero emissions across all scopes by 2050, as part of their long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which underscores their dedication to reducing greenhouse gas emissions in line with global climate goals. The company is actively working towards these targets, having initiated their net-zero journey in 2023. As a player in the pharmaceuticals, biotechnology, and life sciences sector, Viyash Life Sciences is positioned to make a substantial impact on climate change through these commitments and ongoing reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 53,362,700 |
| Scope 2 | 32,333,760 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viyash Life Sciences Private is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
